Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Execution of Imam Khomeini's Order (EIKO) is a massive Iranian parastatal conglomerate that operates under the direct supervision of the Supreme Leader of Iran. Its healthcare activities are primarily conducted through the Barkat Pharmaceutical Group, which is one of the largest pharmaceutical holding companies in the Middle East, controlling approximately 15% of Iran's essential drug market. EIKO gained international prominence for developing COVIran Barekat, Iran's first domestically produced COVID-19 vaccine, through its subsidiary Shifa Pharmed. The organization manages a vast portfolio of assets across multiple industries and operates the Barkat Pharmaceutical Industrial City, the region's largest specialized pharmaceutical zone. Beyond vaccines, EIKO's subsidiaries produce a wide range of generic medicines, active pharmaceutical ingredients (APIs), and advanced cell-based therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Execution of Imam Khomeini's Order.